These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33529849)

  • 1. Treatment retention and abstinence of patients with substance use disorders according to addiction severity and psychiatry comorbidity: A six-month follow-up study in an outpatient unit.
    Daigre C; Rodríguez L; Roncero C; Palma-Álvarez RF; Perea-Ortueta M; Sorribes-Puertas M; Martínez-Luna N; Ros-Cucurull E; Ramos-Quiroga JA; Grau-López L
    Addict Behav; 2021 Jun; 117():106832. PubMed ID: 33529849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Characteristics Predicting Abstinence in Substance Use Disorder Patients With Comorbid Mental Disorders.
    van Hagen LJ; de Waal MM; Christ C; Dekker JJM; Goudriaan AE
    J Dual Diagn; 2019; 15(4):312-323. PubMed ID: 31566115
    [No Abstract]   [Full Text] [Related]  

  • 3. Destination Matters More: Relapse following Hospital-Based Treatment of Substance Use Disorders With and Without Co-Occurring Disorders.
    Andreu M; Balcells-Olivero M; Alcaraz N; Marco O; Bueno L; Gual A; Barrio P
    J Dual Diagn; 2024; 20(2):111-121. PubMed ID: 38367999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polysubstance use by psychiatry inpatients with co-occurring mental health and substance use disorders.
    Timko C; Ilgen M; Haverfield M; Shelley A; Breland JY
    Drug Alcohol Depend; 2017 Nov; 180():319-322. PubMed ID: 28942289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms.
    Rohsenow DJ; Tidey JW; Martin RA; Colby SM; Swift RM; Leggio L; Monti PM
    Addiction; 2017 Oct; 112(10):1808-1820. PubMed ID: 28498504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severity factors associated with borderline personality disorder among misusers in an outpatient sample in Spain.
    Barral C; Daigre C; Bachiller D; Calvo N; Ros-Cucurull E; Gancedo B; Grau-López L; Ferrer M; Casas M; Roncero C
    J Addict Dis; 2017; 36(2):93-96. PubMed ID: 28001490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of telephone monitoring with psychiatry inpatients with co-occurring substance use and mental health disorders.
    Timko C; Harris AHS; Jannausch M; Ilgen M
    Drug Alcohol Depend; 2019 Jan; 194():230-237. PubMed ID: 30466040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of co-occurring substance use on 6 month outcomes for young people seeking mental health treatment.
    Baker KD; Lubman DI; Cosgrave EM; Killackey EJ; Yuen HP; Hides L; Baksheev GN; Buckby JA; Yung AR
    Aust N Z J Psychiatry; 2007 Nov; 41(11):896-902. PubMed ID: 17924242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychiatric comorbidity and severity of dependence on substance users: how it impacts on their health-related quality of life?
    Lozano ÓM; Rojas AJ; Fernández Calderón F
    J Ment Health; 2017 Apr; 26(2):119-126. PubMed ID: 27128492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dropping out of outpatient psychiatric treatment: a preliminary report of a 2-year follow-up of 1500 psychiatric outpatients in Kermanshah, Iran.
    Khazaie H; Rezaie L; de Jong DM
    Gen Hosp Psychiatry; 2013; 35(3):314-9. PubMed ID: 23265950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes From a 10-Week Follow-Up Psychoeducational Program for Dual Diagnosis.
    Chilton J; Crone D; Tyson PJ
    J Dual Diagn; 2018; 14(2):102-110. PubMed ID: 29461932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abstinence duration and psychopathology among addiction outpatients during 18 months of COVID-19.
    Daigre C; Palma-Álvarez RF; Sorribes-Puertas M; Ortega-Hernández G; Perea-Ortueta M; Ros-Cucurull E; Segura L; Colom J; Braquehais MD; Ramos-Quiroga JA; Grau-López L
    Front Psychiatry; 2024; 15():1339730. PubMed ID: 38389986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Problematic substance use among patients in a Swedish outpatient psychiatry setting: staff and manager perceptions of digital options for increased intervention access.
    Petersén E; Augustsson H; Berman AH
    Addict Sci Clin Pract; 2023 Oct; 18(1):65. PubMed ID: 37875999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychiatric factors affecting recovery after a long term treatment program for substance use disorder.
    Daigre C; Perea-Ortueta M; Berenguer M; Esculies O; Sorribes-Puertas M; Palma-Alvarez R; Martínez-Luna N; Ramos-Quiroga JA; Grau-López L
    Psychiatry Res; 2019 Jun; 276():283-289. PubMed ID: 31128488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential relationships between continuity of care practices, engagement in continuing care, and abstinence among subgroups of patients with substance use and psychiatric disorders.
    Schaefer JA; Cronkite RC; Hu KU
    J Stud Alcohol Drugs; 2011 Jul; 72(4):611-21. PubMed ID: 21683043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-national patterns of substance use disorder treatment and associations with mental disorder comorbidity in the WHO World Mental Health Surveys.
    Harris MG; Bharat C; Glantz MD; Sampson NA; Al-Hamzawi A; Alonso J; Bruffaerts R; Caldas de Almeida JM; Cia AH; de Girolamo G; Florescu S; Gureje O; Haro JM; Hinkov H; Karam EG; Karam G; Lee S; Lépine JP; Levinson D; Makanjuola V; McGrath J; Mneimneh Z; Navarro-Mateu F; Piazza M; Posada-Villa J; Rapsey C; Tachimori H; Ten Have M; Torres Y; Viana MC; Chatterji S; Zaslavsky AM; Kessler RC; Degenhardt L;
    Addiction; 2019 Aug; 114(8):1446-1459. PubMed ID: 30835879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic.
    Tsuang D; Cowley D; Ries R; Dunner DL; Roy-Byrne PP
    J Clin Psychiatry; 1995 Dec; 56(12):549-55. PubMed ID: 8530330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cannabis cessation interventions offered to young French users: predictors of follow-up].
    Abdoul H; Le Faou AL; Bouchez J; Touzeau D; Lagrue G
    Encephale; 2012 Apr; 38(2):141-8. PubMed ID: 22516272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment staff's continuity of care practices, patients' engagement in continuing care, and abstinence following outpatient substance-use disorder treatment.
    Schaefer JA; Harris AH; Cronkite RC; Turrubiartes P
    J Stud Alcohol Drugs; 2008 Sep; 69(5):747-56. PubMed ID: 18781250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated treatment of comorbid depression and substance use disorders.
    Charney DA; Paraherakis AM; Gill KJ
    J Clin Psychiatry; 2001 Sep; 62(9):672-7. PubMed ID: 11681761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.